Target intelligence / Profile preview

Lactobacillus reuteri beta-galactosidase (LacA) (LacA)

Target
LacA
Molecular classification
Enzyme, Glycoside hydrolase
01

Overview

Lactobacillus reuteri LacA is a specialized beta-galactosidase enzyme belonging to the Glycoside Hydrolase family 42 (GH42), primarily found in the probiotic bacterium Limosilactobacillus reuteri (formerly Lactobacillus reuteri). Unlike the more common GH2 family beta-galactosidases that specialize in lactose hydrolysis, LacA is specifically adapted to degrade complex galactooligosaccharides (GOS) and alpha-galactosides such as raffinose and stachyose [1, 6, 16]. This enzymatic activity is crucial for the ecological fitness and competitive colonization of L. reuteri within the human gastrointestinal tract, as it allows the bacterium to utilize specific dietary fibers as a primary energy source [1, 2, 10]. In clinical and biotechnological contexts, LacA is considered a key component of synbiotic therapies, where prebiotics like GOS are administered to selectively promote the growth and metabolic activity of the probiotic [3, 4, 10]. By facilitating the breakdown of these substrates, LacA supports the probiotic's ability to modulate the host immune system, strengthen the intestinal barrier, and produce beneficial metabolites like short-chain fatty acids [5, 7, 12]. Furthermore, its activity contributes to the alleviation of symptoms associated with lactose intolerance and infant colic by assisting in the digestion of galactose-containing sugars [11, 12].

Other names
GH42 beta-galactosidaseBeta-D-galactosidaseGalactoside hydrolaseLimosilactobacillus reuteri LacAGalactooligosaccharide hydrolase
02

Mechanism of action

Hydrolysis of terminal beta-galactosyl residues from galactooligosaccharides and other beta-galactosides to provide a carbon source for the probiotic bacterium, thereby enhancing its survival, colonization, and beneficial metabolic activity in the host gastrointestinal tract.

03

Biological functions

Carbohydrate metabolismGalactooligosaccharide degradationBacterial gut colonizationAlpha-galactoside metabolism
04

Disease associations

InflammationInfectionOther
05

Safety considerations

Opportunistic infection in severely immunocompromised patientsTheoretical risk of D-lactic acidosis in short bowel syndromeBacteremia (extremely rare)
06

Interacting drugs

Galactooligosaccharides

3 more in the full profile.

07

Biomarkers

Lactobacillus reuteri abundanceHydrogen breath test resultsStool short-chain fatty acid levels

Beyond the preview

Go deeper on Lactobacillus reuteri beta-galactosidase (LacA) (LacA).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Full profile access

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Full profile access

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Full profile access

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Full profile access

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Full profile access

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Full profile access

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on Lactobacillus reuteri beta-galactosidase (LacA) (LacA).

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call